glp-1 nad Cardiovascular Protection with a Long-Acting Receptor Agonist Liraglutide: An Experimental Update GLP-1 programs the neurovascular landscape:
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 19.Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al
Do not stop semaglutide without consulting your provider
Ozempic users and healthcare providers have noted intestinal blockages are a major concern, given that the drug can cause buildup in the stomach and gallbladder
Varn AR, Zuleta J
Approval of tirzepatide (brand name Mounjaro/Zepbound), an even more efficacious medication, soon followed in 2023
